r/Plus_Therapeutics


Cerenome | CNSide | REYOBIQ | Nasdaq: CNSY
Cerenome Launches CNSide® CSF Molecular Profile Tests

 
New DNA and RNA tests expand CNSide beyond leptomeningeal metastases to molecular profiling across CNS oncology
 
CNSide Diagnostics, LLC, a wholly owned subsidiary of Cerenome, Inc. (Nasdaq: CNSY), today announces the commercial launch of two new cerebrospinal fluid (CSF)-based molecular profiling tests, available to health care professionals in the United States beginning October 12, 2026:
CNSide® CSF Molecular Profile – Solid Tumor (DNA & RNA)
CNSide® CSF Molecular Profile – Hematologic Malignancies (DNA & RNA)
This launch expands the patient population CNSide can serve. While CNSide® CSF Tumor Cell Enumeration (TCE) is focused on patients with suspected or confirmed leptomeningeal metastases (LM), the new Molecular Profile tests extend CSF-based molecular testing to primary central nervous system (CNS) tumors, solid tumors that have metastasized to the CNS, and hematologic malignancies that involve the CNS.
 
“With these two new tests, CNSide can serve more patients with cancer in the CNS and give their physicians information they can act on,” said Russell Bradley, President and General Manager of CNSide Diagnostics, LLC. “Molecular Profile adds DNA and RNA findings, including potentially actionable alterations, to the cellular information CNSide already provides, and extends CNSide beyond LM to primary CNS tumors and hematologic cancers involving the CNS.”
 
The new tests analyze more than 300 cancer-related genes in cell-free DNA and more than 1,600 transcripts by RNA sequencing, enabling broad characterization of genomic and transcriptomic alterations, including sequence variants, copy-number alterations, and gene fusions. The Hematologic Malignancies test also supports molecular assessment of clonality.
 
The approach underlying CNSide CSF Molecular Profile was recently evaluated in a real-world, peer-reviewed study by Albitar et al., investigators at Genomic Testing Cooperative (GTC), published in The Journal of Liquid Biopsy. The study analyzed 1,391 evaluable CSF specimens from patients being evaluated for primary CNS tumors, metastatic CNS disease, and hematologic malignancies involving the CNS. Researchers identified cancer-related molecular findings in 78.4% of evaluable specimens. The study characterized multiple classes of molecular abnormalities, including sequence variants, copy-number and chromosomal alterations, gene fusions, and clonality.
 
CNSide CSF Molecular Profile is offered through CNSide Diagnostics’ collaboration with GTC, announced in July 2026. GTC performs the DNA and RNA sequencing and bioinformatics analysis. CNSide Diagnostics manages test ordering, results delivery, physician support and billing.
 
The launch builds on CNSide’s established experience in CSF-based oncology diagnostics. Since 2020, more than 11,000 CNSide tests have been performed at more than 120 U.S. cancer institutions. The clinical utility of CNSide CSF tumor-cell analysis in LM has been evaluated in 12 peer-reviewed publications, prospective multicenter evidence from the FORESEE clinical study, and real-world clinical experience.
 
Ordering Information
Beginning October 12, 2026, health care professionals may order CNSide CSF Molecular Profile tests through CNSide Diagnostics for patients with primary CNS tumors, solid tumors that have metastasized to the CNS, or hematologic malignancies involving the CNS. For patients with suspected or confirmed LM, Molecular Profile may be ordered on its own or, when clinically appropriate, alongside TCE: TCE detects and quantifies tumor cells, while Molecular Profile characterizes the DNA and RNA alterations of the disease, providing complementary information from the same CSF specimen. Coverage decisions and reimbursement amounts vary by payer and patient benefit design.
 
CNSide CSF Tumor Cell Enumeration is a laboratory-developed test performed by CNSide Diagnostics, LLC in its CLIA-certified, CAP-accredited laboratory in Houston, Texas. CNSide CSF Molecular Profile tests are laboratory-developed tests currently performed for CNSide Diagnostics by Genomic Testing Cooperative, LCA, a CLIA-certified and CAP-accredited reference laboratory. These tests have not been cleared or approved by the U.S. Food and Drug Administration and are available through CNSide Diagnostics to health care professionals in the U.S.
 
Read More on ir.cerenome.com
CNSide Website

IN CASE YOU MISSED IT
Cerenome Shares Updated Corporate Deck

View Presentation

Recent News & Events

Finding One Cancer Cell in Spinal Fluid: The Test Changing Brain Metastasis Care
The BioHub Podcast

Our President and CEO, Dr. Marc Hedrick, and Russell Bradley, President & GM of CNSide Diagnostics, recently joined Benjamin O'Keefe on The BioHub - by Avetix Podcast to discuss how Cerenome is tackling the toughest CNS cancer challenges head-on.
WATCH HERE

Early Disease Detection and Beating CNS Cancers

Base to Base Biotech Podcast

Marc Hedrick, CEO of Cerenome, speaks to the Base to Base Biotech Podcast about a combined approach to tackling central nervous system (CNS) cancers
LISTEN HERE





Cerenome, Inc. (Nasdaq: CNSY) is a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted radiotherapeutics and proprietary data and artificial intelligence. The Company’s CNSide® cerebrospinal fluid diagnostic platform is designed to support the diagnosis, molecular characterization and longitudinal monitoring of patients with CNS cancers. Its lead therapeutic platform, REYOBIQ™ (rhenium-186 obisbemeda) is being developed for leptomeningeal metastases, recurrent glioblastoma and pediatric brain cancer. CerIQ, the Company’s proprietary data analytics and artificial intelligence platform, is being developed to connect and analyze diagnostic, therapeutic, imaging, bioinformatic and operational data across the organization. By bringing these capabilities together, Cerenome is building an integrated CNS oncology platform intended to improve clinical development, generate actionable disease intelligence and advance more precise care for patients with CNS cancers.
Cerenome, Inc., 6420 Levit Green Blvd, Suite 210, Houston, TX 77021, USA, 210-974-6900
Unsubscribe Manage preferences

looks like there’s been a lot of deleting post in the older outdated group which is a clear sign of gatekeeping, though they try to justify by low effort for posting.

Please feel free to voice your concerns here as much as you want.

I am new here and am looking for straight answers on this stock being huge in a few years. Hoping to get a straight, non-AI, dude or chick just hitting me with some straight easy to understand spark notes.

I would do my DD, but it just seems like a lot of hoopla out there these days.